Biomarker ID | 555 |
PMID | 20977276 |
Year | 2011 |
Biomarker | Fructose-bisphosphate aldolase A; Isocitrate dehydrogenase; Citrate synthase; L-Lactate dehydrogenase A; ATP synthase gamma chain; Alpha-enolase; Phosphoglycerate mutase 1; Malate dehydrogenase; Core protein II; Transketolase; 60 kDa heat shock protein; Flotillin 1; 26S protease regulatory subunit 8; Annexin A2; |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated (with Regulation Coefficient): Fructose-bisphosphate aldolase A [1.15]; Isocitrate dehydrogenase [1.09]; Citrate synthase [1.18]; L-Lactate dehydrogenase A [1.40]; ATP synthase gamma chain [1.28]; Alpha-enolase [1.48]; Phosphoglycerate mutase 1 [1.56]; Malate dehydrogenase [1.64]; Core protein II [1.19]; Transketolase [1.31]; 60 kDa heat shock protein [1.83]; Flotillin 1 [1.07]; 26S protease regulatory subunit 8 [1.14]; Annexin A2 [1.29]; |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Gleason 6 Vs Benign Prostate |
Type of Biomarker | Diagnostic |
Cohort | 46 patients were chosen for the study such that 23 had a gleason score of 6 and 23 had a score of 8 or higher. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | Two-Dimensional Differential in Gel Electrophoresis (2-D DIGE) |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |